Generic placeholder image

Current Pharmaceutical Design

Author(s): Emidio Scarpellini*, Bert Broeders, Jolien Schol, Pierangelo Santori, Mariachiara Addarii, Luigi Boccuto, Florencia Carbone, Ludovico Abenavoli and Jan Tack

DOI: 10.2174/1381612829666230328163449

DownloadDownload PDF Flyer Cite As
The Use of Peppermint Oil in Gastroenterology

Page: [576 - 583] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Background: For decades, mint has been used worldwide for its relieving effects against gastrointestinal disturbances. Peppermint is a perennial herb common in Europe and North America. The active ingredient of peppermint oil is menthol and has various gastroenterological and non-gastroenterological uses, especially in the context of functional gastrointestinal disorders (FGIDs).

Methods: We conducted a literature search on the main medical databases for original articles, reviews, meta-analyses, randomized clinical trials, and case series using the following keywords and acronyms and their associations: peppermint oil, gastro-intestinal motility, irritable bowel syndrome, functional dyspepsia, gastrointestinal sensitivity and gastrointestinal endoscopy.

Results: Peppermint oil and its constituents exert smooth muscle relaxant and anti-spasmodic effects on the lower esophageal sphincter, stomach, duodenum, and large bowel. Moreover, peppermint oil can modulate visceral and central nervous system sensitivity. Taken together, these effects suggest using peppermint oil both for improved endoscopic performance and for treating functional dyspepsia and irritable bowel syndrome. Importantly, peppermint oil has an attractive safety profile compared to classical pharmacological treatments, especially in FGIDs.

Conclusion: Peppermint oil is a safe herbal medicine therapy for application in gastroenterology, with promising scientific perspectives and rapidly expanding use in clinical practice.

[1]
Ulbricht C, Costa D, Jill MGS, et al. An evidence-based systematic review of spearmint by the natural standard research collaboration. J Diet Suppl 2010; 7(2): 179-215.
[http://dx.doi.org/10.3109/19390211.2010.486702] [PMID: 22435615]
[2]
Diniz do Nascimento L, Moraes AAB, Costa KS, et al. Bioactive natural compounds and antioxidant activity of essential oils from spice plants: New findings and potential applications. Biomolecules 2020; 10(7): 988.
[http://dx.doi.org/10.3390/biom10070988] [PMID: 32630297]
[3]
Kim YS, Kim JW, Ha NY, Kim J, Ryu HS. Herbal therapies in functional gastrointestinal disorders: A narrative review and clinical implication. Front Psychiatry 2020; 11: 601.
[http://dx.doi.org/10.3389/fpsyt.2020.00601] [PMID: 32754057]
[4]
Czigle S, Bittner Fialová S, Tóth J, Mučaji P, Nagy M. Treatment of gastrointestinal disorders-plants and potential mechanisms of action of their constituents. Molecules 2022; 27(9): 2881.
[http://dx.doi.org/10.3390/molecules27092881] [PMID: 35566230]
[5]
Mearin F, Rey E, Santander C. Irritable bowel syndrome: How to improve decision making in clinical practice. Med Clin 2018; 151(12): 489-97.
[http://dx.doi.org/10.1016/j.medcli.2018.06.020] [PMID: 30243429]
[6]
Wang C, Fang X. Inflammation and overlap of irritable bowel syndrome and functional dyspepsia. J Neurogastroenterol Motil 2021; 27(2): 153-64.
[http://dx.doi.org/10.5056/jnm20175] [PMID: 33795538]
[7]
Wei L, Singh R, Ro S, Ghoshal UC. Gut microbiota dysbiosis in functional gastrointestinal disorders: Underpinning the symptoms and pathophysiology. JGH Open 2021; 5(9): 976-87.
[http://dx.doi.org/10.1002/jgh3.12528] [PMID: 34584964]
[8]
Wang XJ, Camilleri M. Personalized medicine in functional gastrointestinal disorders: Understanding pathogenesis to increase diagnostic and treatment efficacy. World J Gastroenterol 2019; 25(10): 1185-96.
[http://dx.doi.org/10.3748/wjg.v25.i10.1185] [PMID: 30886502]
[9]
Chiarioni G, Pesce M, Fantin A, Sarnelli G. Complementary and alternative treatment in functional dyspepsia. United European Gastroenterol J 2018; 6(1): 5-12.
[http://dx.doi.org/10.1177/2050640617724061] [PMID: 29435308]
[10]
Tillisch K. Complementary and alternative medicine for functional gastrointestinal disorders. Gut 2006; 55(5): 593-6.
[http://dx.doi.org/10.1136/gut.2005.078089] [PMID: 16609129]
[11]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med 2009; 6(7): e1000100.
[http://dx.doi.org/10.1371/journal.pmed.1000100] [PMID: 19621070]
[12]
Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther 1988; 2(2): 101-18.
[http://dx.doi.org/10.1111/j.1365-2036.1988.tb00677.x] [PMID: 2856502]
[13]
Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle. Gastroenterology 1991; 101(1): 55-65.
[http://dx.doi.org/10.1016/0016-5085(91)90459-X] [PMID: 1646142]
[14]
Kim HJ, Wie J, So I, Jung MH, Ha KT, Kim BJ. Menthol modulates pacemaker potentials through TRPA1 channels in cultured interstitial cells of Cajal from murine small intestine. Cell Physiol Biochem 2016; 38(5): 1869-82.
[http://dx.doi.org/10.1159/000445549] [PMID: 27160463]
[15]
Sigmund CJ, McNally EF. The action of a carminative on the lower esophageal sphincter. Gastroenterology 1969; 56(1): 13-8.
[http://dx.doi.org/10.1016/S0016-5085(69)80061-2] [PMID: 5765428]
[16]
Pimentel M, Bonorris GG, Chow EJ, Lin HC. Peppermint oil improves the manometric findings in diffuse esophageal spasm. J Clin Gastroenterol 2001; 33(1): 27-31.
[http://dx.doi.org/10.1097/00004836-200107000-00007] [PMID: 11418786]
[17]
Imagawa A, Hata H, Nakatsu M, et al. Peppermint oil solution is useful as an antispasmodic drug for esophagogastroduodenoscopy, especially for elderly patients. Dig Dis Sci 2012; 57(9): 2379-84.
[http://dx.doi.org/10.1007/s10620-012-2194-4] [PMID: 22562537]
[18]
Papathanasopoulos A, Rotondo A, Janssen P, et al. Effect of acute peppermint oil administration on gastric sensorimotor function and nutrient tolerance in health. Neurogastroenterol Motil 2013; 25(4): e263-71.
[http://dx.doi.org/10.1111/nmo.12102] [PMID: 23489975]
[19]
Goerg KJ, Spilker TH. Effect of peppermint oil and caraway oil on gastrointestinal motility in healthy volunteers: A pharmacodynamic study using simultaneous determination of gastric and gall-bladder emptying and orocaecal transit time. Aliment Pharmacol Ther 2003; 17(3): 445-51.
[http://dx.doi.org/10.1046/j.1365-2036.2003.01421.x] [PMID: 12562459]
[20]
Dalvi SS, Nadkarni PM, Pardesi R, Gupta KC. Effect of peppermint oil on gastric emptying in man: A preliminary study using a radiolabelled solid test meal. Indian J Physiol Pharmacol 1991; 35(3): 212-4.
[PMID: 1791066]
[21]
Mizuno S, Kato K, Ono Y, et al. Oral peppermint oil is a useful antispasmodic for double-contrast barium meal examination. J Gastroenterol Hepatol 2006; 21(8): 1297-301.
[http://dx.doi.org/10.1111/j.1440-1746.2006.04131.x] [PMID: 16872313]
[22]
Micklefield G, Jung O, Greving I, May B. Effects of intraduodenal application of peppermint oil (WS® 1340) and caraway oil (WS® 1520) on gastroduodenal motility in healthy volunteers. Phytother Res 2003; 17(2): 135-40.
[http://dx.doi.org/10.1002/ptr.1089] [PMID: 12601675]
[23]
Micklefield GH, Greving I, May B. Effects of peppermint oil and caraway oil on gastroduodenal motility. Phytother Res 2000; 14(1): 20-3.
[http://dx.doi.org/10.1002/(SICI)1099-1573(200002)14:1<20::AID-PTR542>3.0.CO;2-Z] [PMID: 10641042]
[24]
Asao T, Mochiki E, Suzuki H, et al. An easy method for the intraluminal administration of peppermint oil before colonoscopy and its effectiveness in reducing colonic spasm. Gastrointest Endosc 2001; 53(2): 172-7.
[http://dx.doi.org/10.1067/mge.2000.108477] [PMID: 11174287]
[25]
Karashima Y, Damann N, Prenen J, et al. Bimodal action of menthol on the transient receptor potential channel TRPA1. J Neurosci 2007; 27(37): 9874-84.
[http://dx.doi.org/10.1523/JNEUROSCI.2221-07.2007] [PMID: 17855602]
[26]
Adam B, Liebregts T, Best J, et al. A combination of peppermint oil and caraway oil attenuates the post-inflammatory visceral hyperalgesia in a rat model. Scand J Gastroenterol 2006; 41(2): 155-60.
[http://dx.doi.org/10.1080/00365520500206442] [PMID: 16484120]
[27]
Liu B, Fan L, Balakrishna S, Sui A, Morris JB, Jordt SE. TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain. Pain 2013; 154(10): 2169-77.
[http://dx.doi.org/10.1016/j.pain.2013.06.043] [PMID: 23820004]
[28]
Peiris M, Weerts ZZRM, Aktar R, Masclee AAM, Blackshaw A, Keszthelyi D. A putative anti-inflammatory role for TRPM8 in irritable bowel syndrome-an exploratory study. Neurogastroenterol Motil 2021; 33(9): e14170.
[http://dx.doi.org/10.1111/nmo.14170] [PMID: 34145938]
[29]
Umezu T. Evidence for dopamine involvement in ambulation promoted by menthone in mice. Pharmacol Biochem Behav 2009; 91(3): 315-20.
[http://dx.doi.org/10.1016/j.pbb.2008.07.017] [PMID: 18718482]
[30]
Umezu T, Morita M. Evidence for the involvement of dopamine in ambulation promoted by menthol in mice. J Pharmacol Sci 2003; 91(2): 125-35.
[http://dx.doi.org/10.1254/jphs.91.125] [PMID: 12686756]
[31]
Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: A prospective, randomized trial. J Gastroenterol 1997; 32(6): 765-8.
[http://dx.doi.org/10.1007/BF02936952] [PMID: 9430014]
[32]
Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil®) in the treatment of irritable bowel syndrome: A prospective double blind placebo-controlled randomized trial. Dig Liver Dis 2007; 39(6): 530-6.
[http://dx.doi.org/10.1016/j.dld.2007.02.006] [PMID: 17420159]
[33]
Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010; 55(5): 1385-90.
[http://dx.doi.org/10.1007/s10620-009-0854-9] [PMID: 19507027]
[34]
May B, Köhler S, Schneider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther 2000; 14(12): 1671-7.
[http://dx.doi.org/10.1046/j.1365-2036.2000.00873.x] [PMID: 11121917]
[35]
Rich G, Shah A, Koloski N, et al. A randomized placebo-controlled trial on the effects of Menthacarin, a proprietary peppermint- and caraway-oil-preparation, on symptoms and quality of life in patients with functional dyspepsia. Neurogastroenterol Motil 2017; 29(11): e13132.
[http://dx.doi.org/10.1111/nmo.13132] [PMID: 28695660]
[36]
Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J. Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial. Digestion 2004; 69(1): 45-52.
[http://dx.doi.org/10.1159/000076546] [PMID: 14755152]
[37]
Chey WD, Lacy BE, Cash BD, Epstein M, Corsino PE, Shah SM. A novel, duodenal-release formulation of a combination of caraway oil and L-menthol for the treatment of functional dyspepsia: A randomized controlled trial. Clin Transl Gastroenterol 2019; 10(4): e00021.
[http://dx.doi.org/10.14309/ctg.0000000000000021] [PMID: 30939487]
[38]
Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci 2016; 61(2): 560-71.
[http://dx.doi.org/10.1007/s10620-015-3858-7] [PMID: 26319955]
[39]
Weerts ZZRM, Masclee AAM, Witteman BJM, et al. Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome. Gastroenterology 2020; 158(1): 123-36.
[http://dx.doi.org/10.1053/j.gastro.2019.08.026] [PMID: 31470006]
[40]
Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. J Clin Gastroenterol 2014; 48(6): 505-12.
[http://dx.doi.org/10.1097/MCG.0b013e3182a88357] [PMID: 24100754]
[41]
Alammar N, Wang L, Saberi B, et al. The impact of peppermint oil on the irritable bowel syndrome: A meta-analysis of the pooled clinical data. BMC Complement Altern Med 2019; 19(1): 21.
[http://dx.doi.org/10.1186/s12906-018-2409-0] [PMID: 30654773]
[42]
Asgarshirazi M, Shariat M, Dalili H. Comparison of the effects of ph-dependent peppermint oil and synbiotic lactol (Bacillus coagulans + fructooligosaccharides) on childhood functional abdominal pain: A randomized placebo-controlled study. Iran Red Crescent Med J 2015; 17(4): e23844.
[http://dx.doi.org/10.5812/ircmj.17(4)2015.23844] [PMID: 26023339]
[43]
Anheyer D, Frawley J, Koch AK, et al. Herbal medicines for gastrointestinal disorders in children and adolescents: A systematic review. Pediatrics 2017; 139(6): e20170062.
[http://dx.doi.org/10.1542/peds.2017-0062] [PMID: 28562281]
[44]
Hikichi T, Irisawa A, Sato M, et al. Utility of peppermint oil for endoscopic diagnosis of gastric tumors. Fukushima J Med Sci 2011; 57(2): 60-5.
[http://dx.doi.org/10.5387/fms.57.60] [PMID: 22353652]
[45]
Hiki N, Kurosaka H, Tatsutomi Y, et al. Peppermint oil reduces gastric spasm during upper endoscopy: A randomized, double-blind, double-dummy controlled trial. Gastrointest Endosc 2003; 57(4): 475-82.
[http://dx.doi.org/10.1067/mge.2003.156] [PMID: 12665756]
[46]
Yamamoto N, Nakai Y, Sasahira N, et al. Efficacy of peppermint oil as an antispasmodic during endoscopic retrograde cholangiopancreatography. J Gastroenterol Hepatol 2006; 21(9): 1394-8.
[http://dx.doi.org/10.1111/j.1440-1746.2006.04307.x] [PMID: 16911682]
[47]
Akere A, Otegbayo JA. Complete colonoscopy: impact of patients’ demographics and anthropometry on caecal intubation time. BMJ Open Gastroenterol 2016; 3(1): e000076.
[http://dx.doi.org/10.1136/bmjgast-2016-000076] [PMID: 27110381]
[48]
Bernstein C, Thorn M, Monsees K, Spell R, O’Connor JB. A prospective study of factors that determine cecal intubation time at colonoscopy. Gastrointest Endosc 2005; 61(1): 72-5.
[http://dx.doi.org/10.1016/S0016-5107(04)02461-7] [PMID: 15672059]
[49]
Madhoun MF, Ali T, Tierney WM, Maple JT. Effect of hyoscine N-butylbromide on adenoma detection rate: Meta-analysis of randomized clinical trials. Dig Endosc 2015; 27(3): 354-60.
[http://dx.doi.org/10.1111/den.12340] [PMID: 25115416]
[50]
Shavakhi A, Ardestani SK, Taki M, Goli M, Keshteli AH. Premedication with peppermint oil capsules in colonoscopy: a double blind placebo-controlled randomized trial study. Acta Gastroenterol Belg 2012; 75(3): 349-53.
[PMID: 23082707]
[51]
Al Moussawi H, Al Khatib M, El Ahmar M, et al. The effect of premedication with peppermint oil capsules (Colpermin) prior to colonoscopy: A double blind randomized placebo-controlled trial. Arab J Gastroenterol 2017; 18(4): 220-3.
[http://dx.doi.org/10.1016/j.ajg.2017.12.003] [PMID: 29273467]
[52]
Leiss O, von Bergmann K. Effect of Rowachol on biliary lipid secretion and serum lipids in normal volunteers. Gut 1985; 26(1): 32-7.
[http://dx.doi.org/10.1136/gut.26.1.32] [PMID: 3965364]
[53]
Zong L, Qu Y, Luo DX, et al. Preliminary experimental research on the mechanism of liver bile secretion stimulated by peppermint oil. J Dig Dis 2011; 12(4): 295-301.
[http://dx.doi.org/10.1111/j.1751-2980.2011.00513.x] [PMID: 21791024]
[54]
Haber SL, El-Ibiary SY. Peppermint oil for treatment of irritable bowel syndrome. Am J Health Syst Pharm 2016; 73(2): 22.
[http://dx.doi.org/10.2146/ajhp140801] [PMID: 26721531]
[55]
Weston CF. Anal burning and peppermint oil. Postgrad Med J 1987; 63(742): 717.
[http://dx.doi.org/10.1136/pgmj.63.742.717-a] [PMID: 3422882]
[56]
Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 2002; 72(3): 247-55.
[http://dx.doi.org/10.1067/mcp.2002.126409] [PMID: 12235445]